Progressive Multifocal Intraocular Lens G. Rubiolini M.D. Italy
www.grvision.com Disclosure of finanacial interest Author's
research is partially funded by Imperial Medical Technologies
(Cartersville GA, USA) producing, developing and supplying the
product presented
Slide 2
PURPOSE This is the first clinical trial to evalutate safety
long term visual outcomes in a selected group of patient with
cataract of this "premium" IOL, available in two versions: modified
C style Micro-Incision Plate style Progressive Multifocal lens that
uses a new optical geometry.
Slide 3
Materials and methods 35 patients (20 F,15M. Mid age 56) had
bilateral Progressive Multi-Focal Intraocular Lenses implants with
a non-linear reading add from +3.0 Diopter to
+4.5(progressive)during cataract surgery ( PRESBIOPTICx by IMT,
Cartersville GA USA). Exclusion criteria included but was not
limited to astigmatism >1D, diabetic retinopathy, maculopathy
and previous ocular surgery.
Slide 4
Materials and methods Biometry: IOLMaster Zeiss Target
refraction: emmetropia Facochop procedure (Stellaris B&L) IOL
implantation in the capsular bag. Injector : Medicel VISCOJECT TM
2.2 mm
Slide 5
Materials and Methods E IOLs characteristics Optic 6 mm Length
11 mm (plate) 12 mm (c- loop) AC Depth 5.3 mm A constant 118.4
Sugested IOL formula : Holladay Biometry: IOLMaster Zeiss Target
refraction: emmetropia PRESBIOPTICx Micro Incision PRESBIOPTICx
Modified C
Slide 6
Implanting PRESBIOPTICx TM 18.0D + 4.00 4.10D - 4.30D 19.0D +
3.80 3.90D 4.10D 20.0D + 3.60 3.70D 3.90D 21.0D + 3.40 3.50D 3.70D
22.0D + 3.20 3.30D 3.50D 23.0D + 3.00 3.10D 3.30D First Lens
Implanted - If emmetropia & near vision achieved then the
second lens Implanted is identical. First Lens Implanted - If near
vision is not achieved then second lens can correct the problem.
DIOPTER OPTICAL ADD 2 nd Lens Availability
Slide 7
IOLs surfaces comparisons PRESBIOPTICx HP60CM Imperial Medical
Technologies Cartersville, GA USA Standard Multifocal IOL
Slide 8
Slide 9
RESULTS: 12 to 24 months follow up Total freedom from glasses
was achieved in 28 patients (>80%) with two similar near
addition implants (Standard PRESBIOPTICx). 5 patients received an
extra 0.40D addition for the second eye (Customized PRESBIOPTICx).
Considering this group too, 33 patients (95%) achieved J2 best
uncorrected near visual acuity with bilateral vision. 100%of the
patients achieved 20/25 or better uncorrected visual acuity for
distance. 2 Patients complained some temporary (2-3 months) night
vision problems such as glare, halos and sparkles (5,7%).
Slide 10
CONCLUSION This revolutionary progressive addition system for
multifocal IOLs provides a excellent visual acuity for distance and
near and it can be eventually customized. Full range vision can be
achieved in 95% of the cases. We found a significant reduction of
temporary side effects of multifocal IOLs such as glare, halos and
sparkles (5,7%).